| scholarly article | Q13442814 |
| P50 | author | Cheryl Arrowsmith | Q5092682 |
| Wolfram Tempel | Q28316856 | ||
| Peter J. Brown | Q42713845 | ||
| Yanli Liu | Q55459042 | ||
| Jinrong Min | Q99638529 | ||
| P2093 | author name string | Bryan L Roth | |
| Xi-Ping Huang | |||
| Masoud Vedadi | |||
| Fengling Li | |||
| Mark T Bedford | |||
| Su Qin | |||
| Stephen V Frye | |||
| Jacqueline L Norris | |||
| Samantha G Pattenden | |||
| Guillermo Senisterra | |||
| Nancy Cheng | |||
| Bradley M Dickson | |||
| Lindsey I James | |||
| Brandi M Baughman | |||
| Stephanie H Cholensky | |||
| Jacob I Stuckey | |||
| Cari Sagum | |||
| Karynne Black | |||
| Katherine G Huber | |||
| P2860 | cites work | Polycomb group genes: keeping stem cell activity in balance | Q21563548 |
| CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis | Q24297763 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs | Q24308689 | ||
| Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells | Q24338840 | ||
| Approaching a parameter-free metadynamics | Q27444510 | ||
| Recognition and Specificity Determinants of the Human Cbx Chromodomains | Q27665584 | ||
| Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7) | Q27689473 | ||
| XDS | Q27860472 | ||
| Phasercrystallographic software | Q27860930 | ||
| GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation | Q27860944 | ||
| Polycomb CBX7 has a unifying role in cellular lifespan | Q28188425 | ||
| Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation | Q28586539 | ||
| Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3 | Q28609869 | ||
| How good are my data and what is the resolution? | Q29615314 | ||
| Canonical sampling through velocity rescaling | Q29616131 | ||
| Epigenetic protein families: a new frontier for drug discovery | Q29616621 | ||
| Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer | Q41108314 | ||
| Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein | Q41986525 | ||
| Is JmjC oxygenase catalysis limited to demethylation? | Q42681365 | ||
| CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. | Q43948180 | ||
| Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. | Q44197854 | ||
| Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. | Q53075808 | ||
| Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer | Q53301564 | ||
| From metadynamics to dynamics | Q54323456 | ||
| Changes in the distributions and dynamics of polycomb repressive complexes during embryonic stem cell differentiation | Q30481667 | ||
| Automated design of ligands to polypharmacological profiles. | Q30539786 | ||
| Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins | Q33518291 | ||
| Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus | Q33742024 | ||
| The central role of EED in the orchestration of polycomb group complexes. | Q33815083 | ||
| Probing the probes: fitness factors for small molecule tools | Q34001269 | ||
| RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells | Q34034935 | ||
| The art of the chemical probe | Q34098693 | ||
| Oncogenic role of the chromobox protein CBX7 in gastric cancer | Q34105084 | ||
| The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. | Q34120439 | ||
| (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells | Q34144669 | ||
| Androgen Receptor Drives Cellular Senescence | Q34189267 | ||
| CBX7 is a tumor suppressor in mice and humans | Q34244202 | ||
| Target validation using chemical probes | Q34333826 | ||
| An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1 | Q34341058 | ||
| Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. | Q34354646 | ||
| Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. | Q34355711 | ||
| Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia | Q34403179 | ||
| Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma | Q34641903 | ||
| Regulation of Senescence in Cancer and Aging | Q34665706 | ||
| Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer | Q34808328 | ||
| Down-regulation of DNMT3b in PC3 cells effects locus-specific DNA methylation, and represses cellular growth and migration | Q34829786 | ||
| DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness | Q34987750 | ||
| Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain | Q35108014 | ||
| Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. | Q35472154 | ||
| PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. | Q35582384 | ||
| Role of the chromobox protein CBX7 in lymphomagenesis. | Q35690238 | ||
| Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain | Q36625174 | ||
| Folding dynamics and mechanism of β-hairpin formation | Q36890665 | ||
| Folding mechanism of β-hairpin trpzip2: heterogeneity, transition state and folding pathways | Q37542994 | ||
| Mind the methyl: methyllysine binding proteins in epigenetic regulation | Q38180674 | ||
| Chromobox Homolog 4 Is Correlated with Prognosis and Tumor Cell Growth in Hepatocellular Carcinoma | Q39110553 | ||
| Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells | Q39239895 | ||
| Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination | Q39703639 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 180-187 | |
| P577 | publication date | 2016-01-25 | |
| P1433 | published in | Nature Chemical Biology | Q904026 |
| P1476 | title | A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1 | |
| P478 | volume | 12 |
| Q93200364 | A Degenerate Peptide Library Approach to Reveal Sequence Determinants of Methyllysine-Driven Protein Interactions |
| Q90271673 | A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins |
| Q38726940 | A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors. |
| Q39147132 | A chemical probe toolbox for dissecting the cancer epigenome |
| Q42380933 | A fast, open source implementation of adaptive biasing potentials uncovers a ligand design strategy for the chromatin regulator BRD4. |
| Q92023399 | A novel approach to modelling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma |
| Q91143383 | Accelerated Structural Prediction of Flexible Protein-Ligand Complexes: The SLICE Method |
| Q47153340 | Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors |
| Q48215325 | Aza-amino acid scanning of chromobox homolog 7 (CBX7) ligands. |
| Q33710042 | Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor |
| Q92667844 | C10ORF12 modulates PRC2 histone methyltransferase activity and H3K27me3 levels |
| Q37517517 | CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme. |
| Q64081924 | Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing |
| Q37149776 | Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis |
| Q39423291 | Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation |
| Q38878310 | Chemical probes for methyl lysine reader domains |
| Q90468307 | Chromatin engineering offers an opportunity to advance epigenetic cancer therapy |
| Q36064095 | Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing |
| Q47103361 | Conformational dynamics of the TTD-PHD histone reader module of the UHRF1 epigenetic regulator reveals multiple histone-binding states, allosteric regulation, and druggability |
| Q89879844 | Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins |
| Q36371775 | Developing Spindlin1 small-molecule inhibitors by using protein microarrays |
| Q48273323 | Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2. |
| Q38696296 | EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line. |
| Q92570836 | Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies |
| Q33764436 | Epigenetic regulation of epithelial-mesenchymal transition |
| Q37612483 | Genomic targeting of epigenetic probes using a chemically tailored Cas9 system |
| Q41965081 | How and when does an anticancer drug leave its binding site? |
| Q36135192 | Identification and Structure-Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1. |
| Q41510757 | Molecular structures guide the engineering of chromatin |
| Q58798742 | Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation |
| Q47194910 | Overcoming time scale and finite size limitations to compute nucleation rates from small scale well tempered metadynamics simulations |
| Q92870318 | Protein domain microarrays as a platform to decipher signaling pathways and the histone code |
| Q93119673 | Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists |
| Q89813713 | Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8 |
| Q38748150 | Selective targeting of epigenetic reader domains |
| Q89511226 | Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy |
| Q38826160 | Structural aspects of small-molecule inhibition of methyllysine reader proteins |
| Q38288565 | Structural basis of molecular recognition of helical histone H3 tail by PHD finger domains. |
| Q38749422 | Structure-Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains |
| Q36996285 | Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7. |
| Q55659123 | Structure–Activity Relationships of Cbx7 Inhibitors, Including Selectivity Studies against Other Cbx Proteins. |
| Q48295925 | Targeted tumor detection: guidelines for developing biotinylated diagnostics |
| Q92179985 | Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer |
| Q90468310 | Targeting non-bromodomain chromatin readers |
| Q57826206 | The synthetic histone-binding regulator protein PcTF activates interferon genes in breast cancer cells |
Search more.